A comprehensive analysis of lung cancer samples from TCGA revealed that upregulation of PHF23 increased the 50% inhibitory concentration (IC50) of cisplatin and docetaxel, two commonly used drugs for chemotherapy in NSCLC (Fig. 3A). Here, PHF23 is linked to lung carcinoma.